Tenoten® in the Treatment of Somatoform, Stress-related and Other Neurotic Disorders

Anxiety Clinical Trial

Official title:

International Multicenter, Double-blind, Randomized Placebo-controlled Phase IV Clinical Trial of Different Dosing Regimens of Tenoten® in the Treatment of Anxiety in Patients With Somatoform, Stress-related and Other Neurotic Disorders

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03036293
• Other study ID #: MMH-TN-001
• Status: Completed
• Phase: Phase 4
• Start date: February 8, 2017
• Est. completion date: September 22, 2018

Study information

• Verified date: August 2019
• Source: Materia Medica Holding
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purposes of this study are: - To further examine the efficacy and safety of Tenoten® in the treatment of anxiety in patients with somatoform, stress-related and other neurotic disorders. - To compare the efficacy of two dosing regimens of Tenoten® (4 tablets daily vs.8 tablets daily, both for 12 weeks) in the treatment of anxiety in patients with somatoform, stress-related and other neurotic disorders.

Description:

Design: an international, a multicenter, double-blind, randomized, parallel group placebo-controlled trial to evaluate efficacy and safety of study treatment. The study will enroll outpatient subjects of both genders aged 18-45 years with verified diagnoses of somatoform, stress-related and other neurotic disorders (F43, F45, F48) and signs of clinically relevant anxiety according to The Hospital Anxiety and Depression scale (HADS). After signing the informed consent form to participate in the clinical study the subject will be interviewed (complaints, medical history, concomitant therapy) and objective examination will be performed; the subject will fill HADS scale. The severity of anxiety at screening should be ≥ 11 according to HADS. If the subject meets inclusion criteria and has no exclusion criteria he/she will be enrolled into the study. The investigator will determine the severity of anxiety using НАМ-А scale; the subject will fill EQ-5D-3L questionnaire. At Visit 1 (Day 1) the subject will be randomized into one of the treatment groups: - Group 1: Tenoten® at 2 tablets twice daily (4 tablets/day); - Group 2: Placebo at 2 tablets twice daily (4 tablets/day); - Group 3: Tenoten® at 2 tablets 4 daily (8 tablets/day). - Group 4: Placebo at 2 tablets 4 daily (8 tablets/day). The first dose should be administered at Visit 1 after the visit procedures are completed. Further administration of the study product will be made according to the dosing scheme. The subject will administer the study product and will be followed for 12 weeks during which additional three visits will be made. At Visit 2 (Week 4), Visit 3 (Week 8) and Visit 4 (Week 12) the physician will record patients' complaints and physical examination data, fill HAM-A scale, check the study and concomitant therapy, assess treatment safety and patient compliance with the study treatment. At the final Visit 4 the subject will fill EQ-5D-3L questionnaire and the investigator will fill the Clinical Global Impression Scale Efficacy Index (CGI-EI). Subjects will be allowed to take symptomatic therapy and medications for their co-morbidities during the study, except for the medicines listed in "Prohibited therapy".

Recruitment information / eligibility

• Status: Completed
• Enrollment: 390
• Est. completion date: September 22, 2018
• Est. primary completion date: September 22, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

1. Patients of both sexes aged 18-45 years (inclusive).

2. Patients diagnosed with somatoform, stress-related, and other neurotic disorders (F43, F45, and F48), in accordance with the ICD-10 criteria.

3. A moderate and severe anxiety (HADS score = 11) documented at screening.

4. Patients providing signed Informed Consent form for participation in the clinical trial.

5. Patients of reproductive age (of both sexes) using contraceptives and contraceptive methods during the study and for 30 days after the end of participation in the trial.

Exclusion Criteria:

1. Moderate and severe depression symptoms recorded at screening (HADS score = 11).

2. Organic, including symptomatic, mental disorders (F00-09).

3. Mental and behavioural disorders due to psychoactive substance use (F10-19).

4. Schizophrenia, schizotypal and delusional disorders (F20-29).

5. Mood [affective] disorders(F30-39).

6. Phobic (F40) and other anxiety disorders (F41), obsessive-compulsive disorder (F42), dissociative [conversion] disorders (F44), depersonalization-derealization syndrome (F48.1).

7. Behavioral syndromes associated with physiological disturbances and physical factors (F50-59).

8. Disorders of adult personality and behavior (F60-69).

9. Intellectual disabilities (F70-79).

10. Inflammatory and traumatic brain injuries with permanent neurological deficit.

11. Prior diagnosis of a class III or IV cardiovascular disease (according to the New York Heart Association, 1964)

12. Malignant neoplasms/suspected malignant neoplasms.

13. An allergy/intolerance to any of the components of medications used in the treatment.

14. Malabsorption syndrome (including hereditary or acquired lactase or other disaccharidase deficiency) and galactosemia.

15. Any conditions that, from investigator's point of view, may affect the patient's ability to participate in the trial.

16. Hospitalizations or surgeries scheduled for any date during the participation in the study.

17. Patients who, from investigator's point of view, will fail to comply with the observation requirements of the trial or with the dosing regimen of the study drugs.

18. Use of drugs listed in "Prohibited therapy" within a month prior to enrollment.

19. Drug addiction, alcohol use in the amount over 2 units of alcohol a day.

20. Pregnant or breast-feeding women.

21. Participation in other clinical trials within 3 month prior to the enrollment in this study.

22. Patients are related to the research personnel of the investigative site who are directly involved in the trial, or patients who are the immediate family member of the researcher. The 'immediate family member' includes husband/wife, parents, children or brothers (or sisters), regardless of whether they are natural or adopted.

23. Patients working for OOO "NPF "MATERIA MEDICA HOLDING", i.e. the company's employee, temporary contract worker, or appointed official responsible for carrying out the research (or the immediate relative).

Related Conditions & MeSH terms

• Anxiety
• Neurotic Disorders

Intervention

Drug:
• Tenoten
Tablet for oral use.
• Placebo
Tablet for oral use.

Locations

Country	Name	City	State
Kazakhstan	Kazakh National Medical University named after S.D. Asfendiyarov	Almaty
Kazakhstan	South - Kazakhstan State Pharmaceutical Academy	Shymkent
Russian Federation	Municipal Autonomous Healthcare Institution Order of the Red Banner of Labor City Clinical Hospital No. 1	Chelyabinsk
Russian Federation	Federal State Budgetary Educational Institution of Higher Education "Kazan Medical University" of the Ministry of Healthcare of the Russian Federation	Kazan'
Russian Federation	LLC "City Center for Neurology and Pain Management"	Kazan'
Russian Federation	The State Autonomic Health Care institution "Interregional clinical and diagnostical center"	Kazan'
Russian Federation	Limited Liability Company "Family policlinic no. 4"	Korolev
Russian Federation	Pirogov Russian National Research Medical University	Moscow
Russian Federation	State Budget Health Care institution of Moscow the City "Scientific and practical psychoneurological center n.a. Z.P. Solovyov" of the Administration of Health Care of Moscow City	Moscow
Russian Federation	The State Budget Educational institution of High Professional Training I.M. Sechenov First Moscow State Medical University of Ministry of Health Care of the Russian Federation, Hospital of nervous diseases A.Y. Kozhevnikov	Moscow
Russian Federation	The State Budget Health Care institution of Moscow the City "City clinical hospital No. 12 of the Administration of Health Care of Moscow City"	Moscow
Russian Federation	State budgetary institution of public health services of the Nizhniy Novgorod region "Nizhegorod Regional Clinical Hospital named after NA Semashko"	Nizhny Novgorod
Russian Federation	LLC "City Neurological Center" Sibneyromed "	Novosibirsk
Russian Federation	Pavlov First Saint Petersburg State Medical University/Department of Neurology and Manual Medicine	Saint Petersburg
Russian Federation	Pavlov First Saint Petersburg State Medical University/Department of Neurology with Clinic	Saint Petersburg
Russian Federation	State-Funded Healthcare Institution of the Samara Region "Samara City N.I. Pirogov Clinical Hospital ?1"	Samara
Russian Federation	Saratov State Medical University named after V. I. Razumovsky	Saratov
Russian Federation	The State Budget Educational institution of High Professional Training Smolensk State Medical University of Ministry of Health Care of the Russian Federation, Smolensk regional clinical hospital	Smolensk
Russian Federation	The state budgetary health care institution of the Vladimir region "Regional Clinical Hospital"	Vladimir
Russian Federation	Volgograd State Medical University	Volgograd
Russian Federation	State Institution of Health of the Yaroslavl Region Clinical Hospital No. 8	Yaroslavl
Russian Federation	The State Health Care Institution Yaroslavl region "Clinical Hospital ?8	Yaroslavl'

Sponsors (1)

Lead Sponsor	Collaborator
Materia Medica Holding

Countries where clinical trial is conducted

Kazakhstan,  Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in the Mean HAM-A Score at 12 Weeks of Treatment: 1. Group 1 (Tenoten®, 4 Tablets a Day); 2. Group 3 (Tenoten®, 8 Tablets a Day).	The Hamilton Anxiety Rating Scale (HAM-A). Personality questionnaire designed to identify constitutive anxiety and situational anxiety. The scale consists of 14 items and measures both psychic anxiety and somatic anxiety. Total score is in range 0-56. Includes the symptoms of anxious mood, phobic, emotional, sleep disorders, depressive mood, somatic symptoms - muscular (pain, convulsions, etc.), sensory (e.g. tinnitus), cardiovascular, respiratory, gastrointestinal, genitourinary, neurovegetative. Major role belongs to behaviour during this interview.; Anxiety scoring: =13 - no anxiety; 14-17 - mild anxiety disorder; 18-24 - moderate anxiety disorder; =25 - severe anxiety.; Higher values represent a worse outcome	12 weeks
Secondary	Change From Baseline in the Mean HAM-A Score at 4 Weeks of Treatment: 1.1. Group 1 (Tenoten®, 4 Tablets a Day); 1.2. Group 3 (Tenoten®, 8 Tablets a Day).	The Hamilton Anxiety Rating Scale (HAM-A). Personality questionnaire designed to identify constitutive anxiety and situational anxiety. The scale consists of 14 items and measures both psychic anxiety and somatic anxiety. Total score is in range 0-56. Includes the symptoms of anxious mood, phobic, emotional, sleep disorders, depressive mood, somatic symptoms - muscular (pain, convulsions, etc.), sensory (e.g. tinnitus), cardiovascular, respiratory, gastrointestinal, genitourinary, neurovegetative. Major role belongs to behaviour during this interview.; Anxiety scoring: =13 - no anxiety; 14-17 - mild anxiety disorder; 18-24 - moderate anxiety disorder; =25 - severe anxiety.; Higher values represent a worse outcome	4 weeks
Secondary	The Mean HAM-A Score at 8 Weeks of Treatment: 2.1. Group 1 (Tenoten®, 4 Tablets a Day); 2.2. Group 3 (Tenoten®, 8 Tablets a Day).	The Hamilton Anxiety Rating Scale (HAM-A). Personality questionnaire designed to identify constitutive anxiety and situational anxiety. The scale consists of 14 items and measures both psychic anxiety and somatic anxiety. Total score is in range 0-56. Includes the symptoms of anxious mood, phobic, emotional, sleep disorders, depressive mood, somatic symptoms - muscular (pain, convulsions, etc.), sensory (e.g. tinnitus), cardiovascular, respiratory, gastrointestinal, genitourinary, neurovegetative. Major role belongs to behaviour during this interview.; Anxiety scoring: =13 - no anxiety; 14-17 - mild anxiety disorder; 18-24 - moderate anxiety disorder; =25 - severe anxiety.; Higher values represent a worse outcome	8 weeks
Secondary	Percentage of Patients Had at Least a 50% Improvement in the HAM-A Score: 3.1. Group 1 (Tenoten® 4 Tablets a Day): After 4, 8 and 12 Weeks; 3.2. Group 3 (Tenoten® 8 Tablets a Day): After 4, 8 and 12 Weeks.	The Hamilton Anxiety Rating Scale (HAM-A). Personality questionnaire designed to identify constitutive anxiety and situational anxiety. The scale consists of 14 items and measures both psychic anxiety and somatic anxiety. Total score is in range 0-56. Includes the symptoms of anxious mood, phobic, emotional, sleep disorders, depressive mood, somatic symptoms - muscular (pain, convulsions, etc.), sensory (e.g. tinnitus), cardiovascular, respiratory, gastrointestinal, genitourinary, neurovegetative. Major role belongs to behaviour during this interview.; Anxiety scoring: =13 - no anxiety; 14-17 - mild anxiety disorder; 18-24 - moderate anxiety disorder; =25 - severe anxiety.; Higher values represent a worse outcome	4,8,12 weeks
Secondary	Percentage of Patients With no Anxiety (HAM-A Score <14) in: 4.1. Group 1 (Tenoten®, 4 Tablets a Day); After 4, 8 and 12 Weeks; 4.3. Group 3 (Tenoten®, 4 Tablets a Day); After 4, 8 and 12 Weeks.	The Hamilton Anxiety Rating Scale (HAM-A). Personality questionnaire designed to identify constitutive anxiety and situational anxiety. The scale consists of 14 items and measures both psychic anxiety and somatic anxiety. Total score is in range 0-56. Includes the symptoms of anxious mood, phobic, emotional, sleep disorders, depressive mood, somatic symptoms - muscular (pain, convulsions, etc.), sensory (e.g. tinnitus), cardiovascular, respiratory, gastrointestinal, genitourinary, neurovegetative. Major role belongs to behaviour during this interview.; Anxiety scoring: =13 - no anxiety; 14-17 - mild anxiety disorder; 18-24 - moderate anxiety disorder; =25 - severe anxiety.; Higher values represent a worse outcome	4,8,12 weeks
Secondary	Change From Baseline in the Total EQ-5D-3L Score at 12 Weeks of Treatment in Patients From: 5.1. Group 1 (Tenoten®, 4 Tablets a Day); 5.2. Group 3 (Tenoten®, 8 Tablets a Day).	European Quality of Life Instrument questionnaire (EQ-5D-3L) is designed for the evaluation of the quality of life.The score ranges between 5-15. Higher values represent a worse outcome.	12 weeks
Secondary	Total CGI Scores in Patients From: 6.1. Group 1 (Tenoten®, 4 Tablets a Day); 6.2. Group 3 (Tenoten®, 8 Tablets a Day).	Clinical Global Impession (CGI) provides a brief assessment of the clinician's view of the patient's global functioning prior to and after initiating a study medication. Total range 0-16. Higher values represent a worse outcome	12 weeks